SynthesisFrontiers of medicine2024
Trajectory of COVID-19 response and management strategy in China: scientific rationale driven strategy adjustments.
Synthesis in Frontiers of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 5 citations in OpenAlex.
- Pediatric Acute Poisoning: The Bipolar Evolution of the Poisoning Spectrum from 2019 to 2024 in Southwest China.Journal of clinical medicine · 2026Article
- Changes in pediatric unintentional injury hospitalizations before and after the COVID-19 pandemic: a retrospective analysis.Frontiers in public health · 2026Article
- Assessment of childhood disease patterns in outpatient settings: a retrospective study from 2016 to 2020.Frontiers in pediatrics · 2026Article
- Blood donation trends in Zhejiang Province, 2017-2025: an ecological study before, during, and after COVID-19.Frontiers in public health · 2026Article
- Epidemiological and clinical characteristics of imported malaria patients admitted to a specialized hospital: a retrospective study (2021- June 2026).Frontiers in cellular and infection microbiology · 2026Observational
- Antimicrobial resistance trends among dominant pathogens in six clinical departments of the Fourth Affiliated Hospital of Guangxi Medical University, 2020-2024.Frontiers in public health · 2026Article
- Trends and effectiveness of digital health management in postdischarge coronary artery disease across COVID19 pandemic.NPJ digital medicine · 2025Article
- Research on optimization of emergency supplies customs clearance strategy from the perspective of public health security based on Chinese trade data.Frontiers in public health · 2025Article
- Innovative public strategies in response to COVID-19: A review of practices from China.Health care science · 2024Review
- The critical role of health policy and management in epidemic control: COVID-19 and beyond.Infectious medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pneumonia caused by novel coronavirus SARS-CoV-2 infection in early December 2019, which was later named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO), rapidly spread across the world. China has made extraordinary efforts to this unprecedented pandemic, put its response and control at a very high level of infectious disease management (Category B but with measures for Category A), given top priority to the people and their lives, and balanced the pandemic control and socio-economic development. After more than three years' fighting against this disease, China downgraded the management of COVID-19 to Category B infectious disease on January 8, 2023 and the WHO declared the end of public health emergency on May 5, 2023. However, the ending of pandemic does not mean that the disease is no longer a health threat. Experiences against COVID-19 from China and the whole world should be learned to prepare well for the future public health emergencies. This article gives a systematic review of the trajectory of COVID-19 development in China, summarizes the critical policy arrangements and provides evidence for the adjustment during policy making process, so as to share experiences with international community and contribute to the global health for all humanity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.